Reduced butyrate-producing bacteria and altered metabolic pathways in the gut microbiome of immunoglobulin A nephropathy patients
Abstract Gut-associated lymphoid tissue is central to the production of galactose-deficient IgA1 (Gd-IgA1), a key factor in immunoglobulin A nephropathy (IgAN). Although no major differences in gut microbiome diversity have been reported across IgAN cohorts, functional alterations in microbial compo...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-13629-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849333001907863552 |
|---|---|
| author | Anna Popova Kārlis Rācenis Monta Brīvība Rihards Saksis Mikus Saulīte Baiba Šlisere Egija Berga-Švītiņa Kristīne Oļeiņika Anna Jana Saulīte Jānis Seilis Juta Kroiča Harijs Čerņevskis Aivars Pētersons Jānis Kloviņš Aivars Lejnieks Viktorija Kuzema |
| author_facet | Anna Popova Kārlis Rācenis Monta Brīvība Rihards Saksis Mikus Saulīte Baiba Šlisere Egija Berga-Švītiņa Kristīne Oļeiņika Anna Jana Saulīte Jānis Seilis Juta Kroiča Harijs Čerņevskis Aivars Pētersons Jānis Kloviņš Aivars Lejnieks Viktorija Kuzema |
| author_sort | Anna Popova |
| collection | DOAJ |
| description | Abstract Gut-associated lymphoid tissue is central to the production of galactose-deficient IgA1 (Gd-IgA1), a key factor in immunoglobulin A nephropathy (IgAN). Although no major differences in gut microbiome diversity have been reported across IgAN cohorts, functional alterations in microbial composition may contribute to disease pathogenesis. The study was designed as a cross-sectional study with an embedded prospective cohort component. Forty-eight adults with biopsy-confirmed IgAN—categorized as progressors (eGFR decline > 5 ml/min/1.73 m²/year, n = 23) or nonprogressors (n = 23)—and 23 healthy controls (HC) were recruited. Stool samples underwent metagenomic and functional profiling. Alpha diversity did not differ significantly between IgAN patients and HC. However, butyrate-producing bacteria (Butyrococcus, Agathobacter rectalis) were less abundant in IgAN patients. The sulfoquinovose degradation I pathway, associated with these bacteria, was also reduced. Nucleotide- and nucleoside-biosynthesis pathways were elevated in IgAN. Gd-IgA1 levels correlated with variations in metabolic pathways. Progressors demonstrated enhanced activity in isopropanol biosynthesis, biotin biosynthesis II, and phospholipid biosynthesis pathways. IgAN patients show reduced butyrate-producing bacteria and distinct functional changes in the gut microbiome suggestive of immune activation and inflammation. Progressors exhibit additional metabolic shifts linked to bacterial membrane stabilization. |
| format | Article |
| id | doaj-art-ed3f87ec7a0f4ae78d202945773c251e |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-ed3f87ec7a0f4ae78d202945773c251e2025-08-20T03:46:01ZengNature PortfolioScientific Reports2045-23222025-07-0115111010.1038/s41598-025-13629-5Reduced butyrate-producing bacteria and altered metabolic pathways in the gut microbiome of immunoglobulin A nephropathy patientsAnna Popova0Kārlis Rācenis1Monta Brīvība2Rihards Saksis3Mikus Saulīte4Baiba Šlisere5Egija Berga-Švītiņa6Kristīne Oļeiņika7Anna Jana Saulīte8Jānis Seilis9Juta Kroiča10Harijs Čerņevskis11Aivars Pētersons12Jānis Kloviņš13Aivars Lejnieks14Viktorija Kuzema15Department of Internal Diseases, Riga Stradins UniversityDepartment of Internal Diseases, Riga Stradins UniversityLatvian Biomedical Research and Study CentreLatvian Biomedical Research and Study CentreDepartment of Internal Diseases, Riga Stradins UniversityJoint Laboratory, Pauls Stradins Clinical University HospitalInstitute of Oncology, Riga Stradins UniversityDepartment of Internal Diseases, Riga Stradins UniversityCenter of Nephrology, Pauls Stradins Clinical University HospitalDepartment of Internal Diseases, Riga Stradins UniversityDepartment of Biology and Microbiology, Riga Stradins UniversityDepartment of Internal Diseases, Riga Stradins UniversityDepartment of Internal Diseases, Riga Stradins UniversityLatvian Biomedical Research and Study CentreDepartment of Internal Diseases, Riga Stradins UniversityDepartment of Internal Diseases, Riga Stradins UniversityAbstract Gut-associated lymphoid tissue is central to the production of galactose-deficient IgA1 (Gd-IgA1), a key factor in immunoglobulin A nephropathy (IgAN). Although no major differences in gut microbiome diversity have been reported across IgAN cohorts, functional alterations in microbial composition may contribute to disease pathogenesis. The study was designed as a cross-sectional study with an embedded prospective cohort component. Forty-eight adults with biopsy-confirmed IgAN—categorized as progressors (eGFR decline > 5 ml/min/1.73 m²/year, n = 23) or nonprogressors (n = 23)—and 23 healthy controls (HC) were recruited. Stool samples underwent metagenomic and functional profiling. Alpha diversity did not differ significantly between IgAN patients and HC. However, butyrate-producing bacteria (Butyrococcus, Agathobacter rectalis) were less abundant in IgAN patients. The sulfoquinovose degradation I pathway, associated with these bacteria, was also reduced. Nucleotide- and nucleoside-biosynthesis pathways were elevated in IgAN. Gd-IgA1 levels correlated with variations in metabolic pathways. Progressors demonstrated enhanced activity in isopropanol biosynthesis, biotin biosynthesis II, and phospholipid biosynthesis pathways. IgAN patients show reduced butyrate-producing bacteria and distinct functional changes in the gut microbiome suggestive of immune activation and inflammation. Progressors exhibit additional metabolic shifts linked to bacterial membrane stabilization.https://doi.org/10.1038/s41598-025-13629-5Gut microbiomeImmunoglobulin a nephropathyProgressorsButyrate-producing bacteria |
| spellingShingle | Anna Popova Kārlis Rācenis Monta Brīvība Rihards Saksis Mikus Saulīte Baiba Šlisere Egija Berga-Švītiņa Kristīne Oļeiņika Anna Jana Saulīte Jānis Seilis Juta Kroiča Harijs Čerņevskis Aivars Pētersons Jānis Kloviņš Aivars Lejnieks Viktorija Kuzema Reduced butyrate-producing bacteria and altered metabolic pathways in the gut microbiome of immunoglobulin A nephropathy patients Scientific Reports Gut microbiome Immunoglobulin a nephropathy Progressors Butyrate-producing bacteria |
| title | Reduced butyrate-producing bacteria and altered metabolic pathways in the gut microbiome of immunoglobulin A nephropathy patients |
| title_full | Reduced butyrate-producing bacteria and altered metabolic pathways in the gut microbiome of immunoglobulin A nephropathy patients |
| title_fullStr | Reduced butyrate-producing bacteria and altered metabolic pathways in the gut microbiome of immunoglobulin A nephropathy patients |
| title_full_unstemmed | Reduced butyrate-producing bacteria and altered metabolic pathways in the gut microbiome of immunoglobulin A nephropathy patients |
| title_short | Reduced butyrate-producing bacteria and altered metabolic pathways in the gut microbiome of immunoglobulin A nephropathy patients |
| title_sort | reduced butyrate producing bacteria and altered metabolic pathways in the gut microbiome of immunoglobulin a nephropathy patients |
| topic | Gut microbiome Immunoglobulin a nephropathy Progressors Butyrate-producing bacteria |
| url | https://doi.org/10.1038/s41598-025-13629-5 |
| work_keys_str_mv | AT annapopova reducedbutyrateproducingbacteriaandalteredmetabolicpathwaysinthegutmicrobiomeofimmunoglobulinanephropathypatients AT karlisracenis reducedbutyrateproducingbacteriaandalteredmetabolicpathwaysinthegutmicrobiomeofimmunoglobulinanephropathypatients AT montabriviba reducedbutyrateproducingbacteriaandalteredmetabolicpathwaysinthegutmicrobiomeofimmunoglobulinanephropathypatients AT rihardssaksis reducedbutyrateproducingbacteriaandalteredmetabolicpathwaysinthegutmicrobiomeofimmunoglobulinanephropathypatients AT mikussaulite reducedbutyrateproducingbacteriaandalteredmetabolicpathwaysinthegutmicrobiomeofimmunoglobulinanephropathypatients AT baibaslisere reducedbutyrateproducingbacteriaandalteredmetabolicpathwaysinthegutmicrobiomeofimmunoglobulinanephropathypatients AT egijabergasvitina reducedbutyrateproducingbacteriaandalteredmetabolicpathwaysinthegutmicrobiomeofimmunoglobulinanephropathypatients AT kristineoleinika reducedbutyrateproducingbacteriaandalteredmetabolicpathwaysinthegutmicrobiomeofimmunoglobulinanephropathypatients AT annajanasaulite reducedbutyrateproducingbacteriaandalteredmetabolicpathwaysinthegutmicrobiomeofimmunoglobulinanephropathypatients AT janisseilis reducedbutyrateproducingbacteriaandalteredmetabolicpathwaysinthegutmicrobiomeofimmunoglobulinanephropathypatients AT jutakroica reducedbutyrateproducingbacteriaandalteredmetabolicpathwaysinthegutmicrobiomeofimmunoglobulinanephropathypatients AT harijscernevskis reducedbutyrateproducingbacteriaandalteredmetabolicpathwaysinthegutmicrobiomeofimmunoglobulinanephropathypatients AT aivarspetersons reducedbutyrateproducingbacteriaandalteredmetabolicpathwaysinthegutmicrobiomeofimmunoglobulinanephropathypatients AT janisklovins reducedbutyrateproducingbacteriaandalteredmetabolicpathwaysinthegutmicrobiomeofimmunoglobulinanephropathypatients AT aivarslejnieks reducedbutyrateproducingbacteriaandalteredmetabolicpathwaysinthegutmicrobiomeofimmunoglobulinanephropathypatients AT viktorijakuzema reducedbutyrateproducingbacteriaandalteredmetabolicpathwaysinthegutmicrobiomeofimmunoglobulinanephropathypatients |